INSIGHTS ON EMERGING CAR T THERAPIES

Researchers at Boston Children's Hospital, Dana-Farber Cancer Institute, and Harvard Medical School have developed an innovative regulatory T cell (Treg)-based therapy to address challenges in...

Scientists believe they have identified a way to circumvent the antigen heterogeneity that has challenged chimeric antigen receptor (CAR) T cell treatment in the setting of acute myeloid leukemia...

Researchers from the University of Wisconsin, Cornell, and a consortium of other institutions conducted a retrospective analysis on CD19-directed Chimeric Antigen Receptor T-cell (CAR T-cell)...

Patients with high tumor burden are predisposed to less favorable outcomes after chimeric antigen receptor T-cell (CAR T) therapy, but researchers say radiomic cytoreduction achieved during...

Researchers at Stanford University have conducted a phase 1 clinical trial (#NCT03233854) evaluating the combination of a bispecific chimeric antigen receptor (CAR) T-cell therapy targeting CD19...

The potential for secondary myelodyspastic syndromes (MDS) following chimeric antigen receptor (CAR) T-cell therapy in children with acute lymphoblastic leukemia (ALL) is a real concern,...